medscape.com
Nutrition Strategies to Induce Remission in IBD
Dietary strategies are being studied as active therapies for inducing remission in IBD, not just for symptom control or nutrition. Many patients struggle with malnutrition, and some diets (especially EEN and CDED) have evidence supporting remission in selected studies.
Adult patients with Crohn’s disease or IBD, parents/caregivers of pediatric patients, clinicians managing nutrition in IBD, and researchers studying diet–microbiome interactions.
What To Know
This Medscape summary reports on a presentation at a medical congress describing dietary approaches that can induce remission in many people with IBD, especially Crohn’s disease.
It highlights exclusive enteral nutrition (EEN), the Crohn’s disease exclusion diet (CDED), and other whole‑food strategies, and it stresses that malnutrition is common in IBD and should be screened for. The article summarizes conference remarks rather than a single large randomized trial.
It says some targeted diets (EEN, CDED, CD‑Treat, Tasty & Healthy) have shown remission rates in studies and that EEN can match steroid-level induction and may yield higher mucosal healing in some reports. CDED is presented as a structured whole‑food plan based on EEN and is included in international nutrition guidelines.
Practical issues — adherence, monitoring, and exit strategies — are noted as important, and some diets were easier for patients to follow than exclusive formula therapy. Implementation notes: The piece emphasizes early screening for malnutrition and named screening tools.
It also discusses suspected mechanisms (dietary additives, emulsifiers, and effects on the microbiome and intestinal barrier) but cautions that specific causal factors aren’t established.
This report summarizes a conference presentation and guideline recommendations; it mixes results from multiple studies with varying sizes and designs. Diets like EEN and CDED require clinical supervision and monitoring for nutrition and adherence. The article does not present a single definitive trial or new guideline update.
